Standard BioTools Inc. Interest Income, Operating
Standard BioTools Inc. (LAB) reported Interest Income, Operating of $4.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeOperating · last filed 2026-08-05
- Standard BioTools Inc. interest income, operating for the quarter ending 2026-06-30 was $4.61M, a 88.05% increase year-over-year.
- Standard BioTools Inc. interest income, operating for the quarter ending 2026-03-31 was $3.51M, a 20.49% increase year-over-year.
- Standard BioTools Inc. interest income, operating for the quarter ending 2025-12-31 was $1.66M, a 57.34% decline year-over-year.
- Standard BioTools Inc. interest income, operating for the quarter ending 2025-09-30 was $2.14M, a 55.36% decline year-over-year.
- Standard BioTools Inc. interest income, operating for fiscal 2025 was $9.18M, a 54.56% decline from fiscal 2024.
- Standard BioTools Inc. interest income, operating for fiscal 2024 was $20.20M, a 262.51% increase from fiscal 2023.
- Standard BioTools Inc. interest income, operating for fiscal 2023 was $5.57M, a 150.31% increase from fiscal 2022.
- Standard BioTools Inc. interest income, operating for fiscal 2022 was $2.23M.
| Period end | Interest Income, Operating 3 month | Interest Income, Operating 3 month as first filed | Interest Income, Operating 6 month | Interest Income, Operating 6 month as first filed | Interest Income, Operating 9 month | Interest Income, Operating 9 month as first filed | Interest Income, Operating 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.61M 10-Q · filed 2026-08-05 | $8.12M 10-Q · filed 2026-08-05 | $9.78M derived: sum of 3 quarters · filed 2026-08-05 | $11.92M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $3.51M 10-Q · filed 2026-05-06 | $5.17M derived: sum of 2 quarters · filed 2026-05-06 | $7.31M derived: sum of 3 quarters · filed 2026-05-06 | $9.77M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $3.80M derived: sum of 2 quarters · filed 2026-03-16 | $6.25M derived: sum of 3 quarters · filed 2026-08-05 | $9.18M 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $2.14M 10-Q · filed 2025-11-04 | $4.59M derived: sum of 2 quarters · filed 2026-08-05 | $7.52M 10-Q · filed 2025-11-04 | $11.40M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $2.45M 10-Q · filed 2026-08-05 | $2.46M 10-Q · filed 2025-08-15 | $5.37M 10-Q · filed 2026-08-05 | $5.38M 10-Q · filed 2025-08-15 | $9.26M derived: sum of 3 quarters · filed 2026-08-05 | $14.06M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $2.91M 10-Q · filed 2026-05-06 | $2.92M 10-Q · filed 2025-05-06 | $6.81M derived: sum of 2 quarters · filed 2026-05-06 | $11.60M derived: sum of 3 quarters · filed 2026-05-06 | $16.91M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.69M derived: sum of 2 quarters · filed 2026-03-16 | $13.99M derived: sum of 3 quarters · filed 2026-03-16 | $20.20M 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $4.79M 10-Q · filed 2025-11-04 | $3.94M 10-Q · filed 2024-11-06 | $10.10M derived: sum of 2 quarters · filed 2025-11-04 | $16.30M 10-Q · filed 2025-11-04 | $13.56M 10-Q · filed 2024-11-06 | $21.22M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-06-30 | $5.30M 10-Q · filed 2025-08-15 | $4.44M 10-Q · filed 2024-08-06 | $11.51M 10-Q · filed 2025-08-15 | $9.62M 10-Q · filed 2024-08-06 | $16.43M derived: sum of 3 quarters · filed 2026-03-16 | $16.77M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-03-31 | $6.21M 10-Q · filed 2025-05-06 | $5.17M 10-Q · filed 2024-05-09 | $11.12M derived: sum of 2 quarters · filed 2026-03-16 | $11.46M derived: sum of 3 quarters · filed 2026-03-16 | $11.71M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2023-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $5.26M derived: sum of 2 quarters · filed 2026-03-16 | $5.50M derived: sum of 3 quarters · filed 2026-03-16 | $5.57M 10-K · filed 2026-03-16 | |||
| 2023-09-30 | $340.00K 10-Q · filed 2024-11-06 | $584.00K derived: sum of 2 quarters · filed 2024-11-06 | $656.00K 10-Q · filed 2024-11-06 | ||||
| 2023-06-30 | $244.00K 10-Q · filed 2024-08-06 | $316.00K 10-Q · filed 2024-08-06 | |||||
| 2023-03-31 | $72.00K 10-Q · filed 2024-05-09 | ||||||
| 2022-12-31 | $2.23M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |